{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"3.8","value":"1.44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"The ratio of Mircera dose was calculated as the median (min-max) ratio of starting dose (Week 1) to the dose at Week 17. Participants who withdrew before Week 17 or who were not administered a Mircera dose at Week 17 visit due to the applicable dose adjustment rules were excluded from the ratio computation.","dispersionType":"Full Range","groups":[{"description":"Mircera was administered subcutaneously once every 4 weeks.","id":"OG000","title":"Mircera"}],"paramType":"MEDIAN","populationDescription":"Participants who received a dose of study drug on Week 1 and Week 17 were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Week 1, Week 17","title":"Ratio of Mircera Starting Dose (Week 1) to the Dose at Week 17","type":"SECONDARY","unitOfMeasure":"ratio"}